#1 Clinical Trials Search in Europe

3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid

This article explores the ongoing clinical trials of MK-5475, a novel drug being investigated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). MK-5475 is an inhalation powder containing the active substance 3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid. These trials aim to assess the drug’s efficacy, safety, and potential to improve the quality of life for patients with these challenging respiratory conditions.

Table of Contents

What is MK-5475?

MK-5475 is an experimental drug being developed by Merck & Co., Inc. Its full chemical name is 3-(4-{(5S)-4-AMINO-2-[6-CHLORO-1-(3,3,4,4,4-PENTAFLUOROBUTYL)-1H-INDAZOL-3-YL]-5-METHYL-6-OXO6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDIN-5-YL}PHENYL)PROPANOIC ACID. This long name describes its complex chemical structure[1]. For simplicity, we’ll refer to it as MK-5475 throughout this article.

What Conditions Does MK-5475 Treat?

MK-5475 is being studied as a potential treatment for two main conditions:

  1. Pulmonary Arterial Hypertension (PAH): This is a rare but serious condition where the blood pressure in the arteries of the lungs is too high. It can lead to shortness of breath, fatigue, and eventually heart failure[1].
  2. Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD): This is a condition where high blood pressure in the lungs occurs as a complication of COPD, a group of lung diseases that block airflow and make it difficult to breathe[2].

How Does MK-5475 Work?

While the exact mechanism of action is not fully described in the provided information, drugs for pulmonary hypertension typically work by relaxing and widening the blood vessels in the lungs. This helps to reduce the blood pressure in these vessels and improve blood flow. MK-5475 likely works in a similar way, but its specific action may be unique and is still being studied[1][2].

How is MK-5475 Administered?

MK-5475 is administered as an inhalation powder. This means that patients breathe the medication directly into their lungs using an inhaler device. The maximum daily dose being studied is 380 micrograms[1][2].

Current Clinical Trials

MK-5475 is currently being studied in two main clinical trials:

  1. Phase 2/3 Trial for PAH: This study is evaluating the safety and effectiveness of MK-5475 in adults with various forms of PAH. It’s looking at how the drug affects things like the resistance in lung blood vessels and how far patients can walk in 6 minutes (a standard test for lung function)[1].
  2. Phase 2a Trial for PH-COPD: This study is testing MK-5475 in adults who have pulmonary hypertension associated with COPD. It’s primarily looking at how the drug affects patients’ ability to walk and their overall lung function[2].

Potential Benefits of MK-5475

Based on the ongoing clinical trials, researchers hope that MK-5475 might provide several benefits:

  • Improved ability to walk and be physically active
  • Reduced pressure in the lung blood vessels
  • Better overall lung function
  • Improved quality of life for patients with PAH or PH-COPD

However, it’s important to note that these potential benefits are still being studied and are not yet proven[1][2].

Possible Side Effects

As MK-5475 is still in clinical trials, the full range of possible side effects is not yet known. The trials are carefully monitoring for any adverse events (side effects) and how many patients might need to stop taking the drug due to these effects. This information will be crucial in determining the overall safety of MK-5475[1][2].

Who Might Be Eligible for MK-5475 Treatment?

Based on the current clinical trials, patients who might be eligible for MK-5475 treatment include:

  • Adults aged 18 and older with various forms of PAH, including idiopathic PAH, heritable PAH, and PAH associated with certain conditions like connective tissue disease or HIV[1].
  • Adults aged 40 to 85 with pulmonary hypertension associated with COPD[2].

However, there are many specific criteria that determine eligibility, including the severity of the condition, other medical issues, and current medications. Only a healthcare provider can determine if someone might be eligible for a clinical trial or, in the future, for treatment with MK-5475 if it becomes approved[1][2].

Aspect PAH Trial PH-COPD Trial
Study Phase Phase 2/3 Phase 2a
Primary Endpoint Change in PVR (Phase 2) and 6MWD (Phase 3) at 12 weeks Change in 6MWD at 24 weeks
Key Secondary Endpoints Changes in 6MWD, hemodynamic parameters, WHO Functional Class Changes in NT-proBNP levels, WHO Functional Class
Study Duration 24 weeks (base period) 24 weeks (double-blind) + 18 months (extension)
Dosage Up to 380 μg daily 380 μg daily
Key Inclusion Criteria PAH diagnosis, specific hemodynamic criteria, WHO-FC II-IV PH-COPD diagnosis, specific hemodynamic criteria, WHO-FC II-IV
Key Exclusion Criteria Other types of PH, significant left heart disease, severe lung disease Other types of PH, significant left heart disease, recent COPD exacerbation

FAQ

  • What is MK-5475 and what conditions is it being tested for? MK-5475 is an investigational drug in the form of an inhalation powder. It is being tested for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
  • How is MK-5475 administered? MK-5475 is administered as an inhalation powder, which means patients inhale the medication directly into their lungs.
  • What are the main goals of the clinical trials for MK-5475? The main goals of the clinical trials are to evaluate the efficacy and safety of MK-5475. Specifically, they aim to assess its effects on pulmonary vascular resistance, 6-minute walk distance, and other important measures of lung and heart function in patients with PAH and PH-COPD.
  • Who can participate in these clinical trials? Eligibility criteria vary between the trials, but generally include adults diagnosed with PAH or PH-COPD, meeting specific hemodynamic criteria, and having certain functional classifications. There are also exclusion criteria, such as having certain other medical conditions or using specific medications.
  • How long do the clinical trials for MK-5475 last? The duration of the trials varies. For example, the PAH trial has a 24-week base period, while the PH-COPD trial includes a 24-week double-blind period followed by an 18-month extension period.

Ongoing Clinical Trials on 3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid

  • Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

    Not recruiting

    2 1
    Investigated drugs:
    Austria Belgium France Germany Italy Spain

  • Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

    Not recruiting

    4 1
    Investigated drugs:
    Belgium France Germany Greece Italy Poland +1

Glossary

  • Pulmonary Arterial Hypertension (PAH): A type of high blood pressure that affects the arteries in the lungs and the right side of the heart.
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases that cause airflow blockage and breathing-related problems.
  • Pulmonary Vascular Resistance (PVR): The resistance that must be overcome to push blood through the circulatory system in the lungs.
  • 6-Minute Walk Distance (6MWD): A test that measures the distance a person can walk quickly on a flat, hard surface in 6 minutes, used to assess exercise capacity.
  • World Health Organization (WHO) Functional Class: A system used to classify the severity of symptoms in patients with pulmonary hypertension.
  • N-terminal pro B-type natriuretic peptide (NT-proBNP): A hormone released by the heart in response to changes in pressure inside the heart, used as a marker of heart stress.
  • Hemodynamic parameters: Measurements related to blood flow through the cardiovascular system.
  • Right Heart Catheterization (RHC): A procedure used to diagnose heart conditions by inserting a thin tube into the right side of the heart to measure blood pressure and flow.
  • Pulmonary Function Testing (PFT): A group of tests that measure how well the lungs take in and release air and how well they move gases such as oxygen into the body's circulation.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-mk-5475-for-adults-with-pulmonary-arterial-hypertension/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mk-5475-for-adults-with-pulmonary-hypertension-and-copd/